

# Jean-Luc Teillaud

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9308798/publications.pdf>

Version: 2024-02-01

67  
papers

3,399  
citations

186209

28  
h-index

149623

56  
g-index

95  
all docs

95  
docs citations

95  
times ranked

4393  
citing authors

#	ARTICLE	IF	CITATIONS
1	BMFPs, a versatile therapeutic tool for redirecting a preexisting Epstein-Barr virus antibody response toward defined target cells. <i>Science Advances</i> , 2022, 8, eabl4363.	4.7	2
2	SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma. <i>Blood</i> , 2022, 139, 1160-1176.	0.6	11
3	Intratumoral plasma cells: More than a predictive marker of response to anti-PD-L1 treatment in lung cancer?. <i>Cancer Cell</i> , 2022, 40, 240-243.	7.7	4
4	Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer Patients. <i>Frontiers in Immunology</i> , 2021, 12, 626776.	2.2	39
5	Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation. <i>Frontiers in Immunology</i> , 2021, 12, 698604.	2.2	35
6	A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy. <i>Oncot Immunology</i> , 2020, 9, 1770565.	2.1	2
7	Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1561-1572.	2.0	6
8	Tertiary Lymphoid Structures: An Anti-tumor School for Adaptive Immune Cells and an Antibody Factory to Fight Cancer?. <i>Frontiers in Immunology</i> , 2017, 8, 830.	2.2	54
9	Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus?. <i>Frontiers in Immunology</i> , 2017, 8, 950.	2.2	11
10	Inhibitory IgG Receptor-Expressing Cells: The Must-Have Accessory for Anti-CD40 Immunomodulatory mAb Efficacy. <i>Cancer Cell</i> , 2016, 29, 771-773.	7.7	3
11	Presence of B Cells in Tertiary Lymphoid Structures Is Associated with a Protective Immunity in Patients with Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 832-844.	2.5	564
12	Single-Domain Antibody-Based and Linker-Free Bispecific Antibodies Targeting Fc $\gamma$ RIII Induce Potent Antitumor Activity without Recruiting Regulatory T Cells. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1481-1491.	1.9	63
13	High lipid content of irradiated human melanoma cells does not affect cytokine-matured dendritic cell function. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 3-15.	2.0	4
14	Effect of zinc on human IgG1 and its Fc $\gamma$ R interactions. <i>Immunology Letters</i> , 2012, 143, 60-69.	1.1	10
15	Human Macrophages and Dendritic Cells Can Equally Present MART-1 Antigen to CD8+ T Cells after Phagocytosis of Gamma-Irradiated Melanoma Cells. <i>PLoS ONE</i> , 2012, 7, e40311.	1.1	50
16	The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. <i>Frontiers in Immunology</i> , 2011, 2, 66.	2.2	9
17	A Differential Concentration-Dependent Effect of IVIg on Neutrophil Functions: Relevance for Anti-Microbial and Anti-Inflammatory Mechanisms. <i>PLoS ONE</i> , 2011, 6, e26469.	1.1	38
18	Modulation of tumor immunity by therapeutic monoclonal antibodies. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 111-124.	2.7	24

#	ARTICLE	IF	CITATIONS
19	Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. <i>Blood</i> , 2010, 116, 926-934.	0.6	183
20	Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 355-366.	0.6	284
21	Impact of Glycosylation on Effector Functions of Therapeutic IgG. <i>Pharmaceuticals</i> , 2010, 3, 146-157.	1.7	132
22	Le mot des coordinateurs. <i>Medicine/Sciences</i> , 2009, 25, 995-996.	0.0	3
23	Llama single-domain antibodies directed against nonconventional epitopes of tumor-associated carcinoembryonic antigen absent from nonspecific cross-reacting antigen. <i>FEBS Journal</i> , 2009, 276, 3881-3893.	2.2	58
24	Activating and inhibitory Fc $\gamma$ 3 receptors in immunotherapy: being the actor or being the target. <i>Expert Review of Clinical Immunology</i> , 2009, 5, 735-747.	1.3	17
25	Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of Fc $\gamma$ 3RIIIA/CD16. <i>British Journal of Haematology</i> , 2008, 140, 635-643.	1.2	115
26	A human anti-CD monoclonal antibody selected for enhanced Fc $\gamma$ 3RIII engagement clears RhD <sup>+</sup> autologous red cells in human volunteers as efficiently as polyclonal anti-CD antibodies. <i>British Journal of Haematology</i> , 2008, 141, 109-119.	1.2	47
27	A novel subset of NK cells expressing high levels of inhibitory Fc $\gamma$ 3RIIB modulating antibody-dependent function. <i>Journal of Leukocyte Biology</i> , 2008, 84, 1511-1520.	1.5	36
28	Activation of Human Peripheral IgM <sup>+</sup> B Cells Is Transiently Inhibited by BCR-Independent Aggregation of Fc $\gamma$ 3RIIB. <i>Journal of Immunology</i> , 2008, 181, 5350-5359.	0.4	13
29	R603: A New Low Dose Efficient Anti-CD20 Immunotherapy for CLL Patients?. <i>Blood</i> , 2008, 112, 4155-4155.	0.6	0
30	Fc $\gamma$ 3R: The key to optimize therapeutic antibodies?. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 62, 26-33.	2.0	86
31	Can NK Cells Play a Role in Anti-CD20 Immunotherapy for CLL Patients?.. <i>Blood</i> , 2007, 110, 3103-3103.	0.6	0
32	Selection of a human anti-RhD monoclonal antibody for therapeutic use: Impact of IgG glycosylation on activating and inhibitory Fc $\gamma$ 3R functions. <i>Clinical Immunology</i> , 2006, 118, 170-179.	1.4	77
33	Molecular aspects of human Fc $\gamma$ 3R interactions with IgG: Functional and therapeutic consequences. <i>Immunology Letters</i> , 2006, 106, 111-118.	1.1	47
34	Tumor-infiltrating B cell immunoglobulin variable region gene usage in invasive ductal breast carcinoma. <i>Pathology and Oncology Research</i> , 2005, 11, 92-97.	0.9	22
35	Novel Ganglioside Antigen Identified by B Cells in Human Medullary Breast Carcinomas: The Proof of Principle Concerning the Tumor-Infiltrating B Lymphocytes. <i>Journal of Immunology</i> , 2005, 175, 2278-2285.	0.4	82
36	Combining IR spectroscopy with fluorescence imaging in a single microscope: Biomedical applications using a synchrotron infrared source (invited). <i>Review of Scientific Instruments</i> , 2002, 73, 1357-1360.	0.6	42

#	ARTICLE	IF	CITATIONS
37	Regulated Expression and Inhibitory Function of Fc $\gamma$ RIIb in Human Monocytic Cells. <i>Journal of Biological Chemistry</i> , 2002, 277, 5082-5089.	1.6	120
38	Cytokine production and T-cell activation by macrophage-dendritic cells generated for therapeutic use. <i>British Journal of Haematology</i> , 2001, 114, 671-680.	1.2	5
39	Differential Modulation of Stimulatory and Inhibitory Fc $\gamma$ Receptors on Human Monocytes by Th1 and Th2 Cytokines. <i>Journal of Immunology</i> , 2001, 166, 531-537.	0.4	215
40	The Fc Receptor for IgG Expressed in the Villus Endothelium of Human Placenta Is Fc $\gamma$ RIIb2. <i>Journal of Immunology</i> , 2001, 166, 3882-3889.	0.4	77
41	Selective PCR Amplification of Functional Immunoglobulin Light Chain from Hybridoma Containing the Aberrant MOPC 21-Derived V $\lambda$ by PNA-Mediated PCR Clamping. <i>BioTechniques</i> , 1999, 26, 818-822.	0.8	34
42	Immunoglobulin variable regions usage by B-lymphocytes infiltrating a human breast medullary carcinoma. <i>Immunology Letters</i> , 1999, 65, 143-151.	1.1	24
43	Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. <i>Oncogene</i> , 1999, 18, 551-557.	2.6	80
44	A tumor specific single chain antibody dependent gene expression system. <i>Oncogene</i> , 1999, 18, 559-564.	2.6	7
45	Generation of phagocytic MAK and MAC-DC for therapeutic use. <i>Experimental Hematology</i> , 1999, 27, 751-761.	0.2	28
46	In vivo induction of functional Fc $\gamma$ RI (CD64) on neutrophils and modulation of blood cytokine mRNA levels in cancer patients treated with G-CSF (rMetHuG-CSF). <i>British Journal of Haematology</i> , 1998, 100, 550-556.	1.2	27
47	Soluble Fc $\gamma$ Receptor, Fc $\gamma$ RIIa2, is Present in Two Forms in Human Serum and is Increased in Patients: With Stage C Chronic Lymphocytic Leukemia. <i>Leukemia and Lymphoma</i> , 1997, 26, 317-326.	0.6	8
48	A New Set of Monoclonal Antibodies Against Human Fc $\gamma$ RII (CD32) and Fc $\gamma$ RIII (CD16): Characterization and Use in Various Assays. <i>Hybridoma</i> , 1997, 16, 519-528.	0.9	35
49	Epitope Mapping and Tight-Binding Inhibition with Monoclonal Antibodies Directed against Escherichia coli Glucosamine 6-phosphate Synthase. <i>Archives of Biochemistry and Biophysics</i> , 1995, 324, 391-400.	1.4	2
50	Detection and quantification of secreted soluble Fc $\gamma$ RIIA in human sera by an enzyme-linked immunosorbent assay. <i>Journal of Immunological Methods</i> , 1993, 166, 1-10.	0.6	24
51	Possibilities of Interference with the Immune System of Tumor Bearers by Non-Lymphoid Fc $\gamma$ RII Expressing Tumor Cells. <i>Immunobiology</i> , 1992, 185, 415-425.	0.8	11
52	Structural Bases of Fc $\gamma$ Receptor Functions. <i>Immunological Reviews</i> , 1992, 125, 49-76.	2.8	137
53	In vitro inhibition of tumor B cell growth by IgG-BF-producing Fc $\gamma$ RII+T cell hybridoma and by immunoglobulin G-binding factors. <i>Immunologic Research</i> , 1992, 11, 296-304.	1.3	2
54	Evaluation of circulating tumor necrosis factor- $\alpha$ in patients with gynecological malignancies. <i>International Journal of Cancer</i> , 1991, 48, 375-378.	2.3	15

#	ARTICLE	IF	CITATIONS
55	Regulation of IgG production by suppressor Fc $\gamma$ RII+ T hybridomas. European Journal of Immunology, 1990, 20, 55-61.	1.6	14
56	Recombinant interleukin 2-activated natural killer cells regulate IgG2a production. European Journal of Immunology, 1990, 20, 1781-1787.	1.6	21
57	Involvement of FcR+ T cells and of IGG-BF in the control of myeloma cells. Molecular Immunology, 1990, 27, 1209-1217.	1.0	14
58	Some cellular and molecular characteristics of high and low tumorigenicity variants of polyoma-virus transformed cells. Molecular Immunology, 1990, 27, 1219-1228.	1.0	4
59	Fc $\gamma$ RII expression in resting and activated B lymphocytes. European Journal of Immunology, 1989, 19, 1379-1385.	1.6	76
60	Regulatory effects of IgG-BF on hybridoma B cells. Molecular characterization of variant cell lines. Molecular Immunology, 1988, 25, 1133-1142.	1.0	7
61	Molecular heterogeneity of murine IgG-BF. Molecular Immunology, 1986, 23, 1183-1191.	1.0	9
62	Molecular characterization of two Ia-like antigens in marmoset. Immunogenetics, 1984, 19, 155-161.	1.2	2
63	The identification of monoclonal class switch variants by sib selection and an ELISA assay. Journal of Immunological Methods, 1984, 74, 307-315.	0.6	79
64	Involvement of human membrane-associated complement components in the rosette formation between Marmoset red blood cells and human leukocytes. Cellular Immunology, 1982, 66, 254-268.	1.4	2
65	Analysis of DR-like molecules on a marmoset Epstein-Barr virus-induced cell line using a monomorphic anti-human HLA-DR monoclonal antibody. European Journal of Immunology, 1982, 12, 446-448.	1.6	8
66	Monoclonal antibodies as a tool for phylogenetic studies of major histocompatibility antigens and ? 2-microglobulin. Immunogenetics, 1982, 15, 377-384.	1.2	48
67	Fc $\gamma$ R expressed on T-cell hybrids: Specificity, behavior and relationship with Ia antigens. Cellular Immunology, 1981, 63, 349-361.	1.4	9